A short presentation followed by an interactive discussion exploring the opportunity in fusion-derived isotopes for diagnostics and therapeutics.

• How big are medical isotope markets and how entrenched are the incumbents?
• Can fusion-derived beat traditional products on reliability, purity, and cost?
• What's the capital pathway from proof of concept through full commercial scale, and from diagnostic isotopes into therapeutics?
• How valuable is dual capability in diagnostic and therapeutic isotopes?
• What attracts healthcare and pharma companies to new isotope producers?

Moderated by: Melanie Windridge, Co-founder - FusionX